Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMT-009
- Development stage
- Phase 2
- Lead developer
- Immunitas Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMT-009 is a first-in-class, humanized, Fc-attenuated IgG1 monoclonal antibody designed to inhibit CD161 (KLRB1), a C-type lectin receptor expressed on natural killer (NK) cells and memory T cells. By blocking the interaction between CD161 and its ligand CLEC2D (LLT1), IMT-009 aims to overcome immune suppression in the tumor microenvironment, enhancing NK cell degranulation and T cell-mediated killing of tumor cells. Developed by Immunitas Therapeutics using a single-cell genomics platform, the drug is being investigated for the treatment of advanced solid tumors (including microsatellite stable colorectal cancer, NSCLC, and HNSCC) and hematological malignancies (lymphomas). It is being studied both as a monotherapy and in combination with other agents like fruquintinib.
- Other names
- IMT
02
Targets
KLRB1 (C-type lectin-like receptor CD161)
Beyond the preview
Go deeper on IMT-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMT-009.